192 related articles for article (PubMed ID: 36037447)
1. Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors.
Basak S; Li Y; Tao S; Daryaee F; Merino J; Gu C; Delker SL; Phan JN; Edwards TE; Walker SG; Tonge PJ
J Med Chem; 2022 Sep; 65(17):11854-11875. PubMed ID: 36037447
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.
Zuo K; Liang L; Du W; Sun X; Liu W; Gou X; Wan H; Hu J
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481250
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor.
Mochalkin I; Knafels JD; Lightle S
Protein Sci; 2008 Mar; 17(3):450-7. PubMed ID: 18287278
[TBL] [Abstract][Full Text] [Related]
4. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
5. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
6. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
[TBL] [Abstract][Full Text] [Related]
7. Impact of Target Turnover on the Translation of Drug-Target Residence Time to Time-Dependent Antibacterial Activity.
Basu R; Wang N; Basak S; Daryaee F; Babar M; Allen EK; Walker SG; Haley JD; Tonge PJ
ACS Infect Dis; 2021 Sep; 7(9):2755-2763. PubMed ID: 34357770
[TBL] [Abstract][Full Text] [Related]
8. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
Erwin AL
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
12. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
13. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
[TBL] [Abstract][Full Text] [Related]
14. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
15. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
[TBL] [Abstract][Full Text] [Related]
16. Selective mapping of chemical space for Pseudomonas aeruginosa deacetylase LpxC inhibitory potential.
Kadam RU; Garg D; Roy N
Chem Biol Drug Des; 2008 Jan; 71(1):45-56. PubMed ID: 18086152
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
[TBL] [Abstract][Full Text] [Related]
18. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
[TBL] [Abstract][Full Text] [Related]
19. LpxC inhibition: Potential and opportunities with carbohydrate scaffolds.
Amudala S; Sumit ; Aidhen IS
Carbohydr Res; 2024 Mar; 537():109057. PubMed ID: 38402732
[TBL] [Abstract][Full Text] [Related]
20. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
